185 related articles for article (PubMed ID: 30075728)
21. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.
He T; Li K; Roberts MS; Spaulding AC; Ayer T; Grefenstette JJ; Chhatwal J
Ann Intern Med; 2016 Jan; 164(2):84-92. PubMed ID: 26595252
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C.
Marco A; Esteban JI; Solé C; da Silva A; Ortiz J; Roget M; Sarriera C; Teixidó N; Guerrero RA; Caylà JA
J Hepatol; 2013 Jul; 59(1):45-51. PubMed ID: 23523577
[TBL] [Abstract][Full Text] [Related]
23. Why is there still hepatitis C transmission in Australian prisons? A case report.
Harkness B; Levy M; Evans R; Wenke J
Harm Reduct J; 2017 Nov; 14(1):75. PubMed ID: 29178927
[TBL] [Abstract][Full Text] [Related]
24. Who goes first? Understanding hepatitis C risk among injecting networks in the prison setting.
Lafferty L; Rance J; Treloar C
Drug Alcohol Depend; 2018 Feb; 183():96-101. PubMed ID: 29245104
[TBL] [Abstract][Full Text] [Related]
25. Substitution treatment and HCV/HIV-infection in a sample of 31 German prisons for sentenced inmates.
Schulte B; Stöver H; Thane K; Schreiter C; Gansefort D; Reimer J
Int J Prison Health; 2009; 5(1):39-44. PubMed ID: 25758928
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of hepatitis C virus infection among prisoners in Iran: a systematic review and meta-analysis.
Behzadifar M; Gorji HA; Rezapour A; Bragazzi NL
Harm Reduct J; 2018 May; 15(1):24. PubMed ID: 29739400
[TBL] [Abstract][Full Text] [Related]
27. Overview of harm reduction in prisons in seven European countries.
Sander G; Scandurra A; Kamenska A; MacNamara C; Kalpaki C; Bessa CF; Laso GN; Parisi G; Varley L; Wolny M; Moudatsou M; Pontes NH; Mannix-McNamara P; Libianchi S; Antypas T
Harm Reduct J; 2016 Oct; 13(1):28. PubMed ID: 27717368
[TBL] [Abstract][Full Text] [Related]
28. Tattooing in prisons--not such a pretty picture.
Hellard ME; Aitken CK; Hocking JS
Am J Infect Control; 2007 Sep; 35(7):477-80. PubMed ID: 17765561
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis C virus infection in South Australian prisoners: seroprevalence, seroconversion, and risk factors.
Miller ER; Bi P; Ryan P
Int J Infect Dis; 2009 Mar; 13(2):201-8. PubMed ID: 18790659
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030.
Bruggmann P; Blach S; Deltenre P; Fehr J; Kouyos R; Lavanchy D; Müllhaupt B; Rauch A; Razavi H; Schmid P; Semela D; Stoeckle M; Negro F
Swiss Med Wkly; 2017; 147():w14543. PubMed ID: 29120012
[TBL] [Abstract][Full Text] [Related]
31. Use of telehealth to increase treatment access for prisoners with chronic hepatitis C.
Halder A; Li VG; Sebastian M; Nazareth S; Tuma R; Cheng W; Doyle A
Intern Med J; 2021 Aug; 51(8):1344-1347. PubMed ID: 34423535
[TBL] [Abstract][Full Text] [Related]
32. A prospective study of hepatitis C incidence in Australian prisoners.
Luciani F; Bretaña NA; Teutsch S; Amin J; Topp L; Dore GJ; Maher L; Dolan K; Lloyd AR;
Addiction; 2014 Oct; 109(10):1695-706. PubMed ID: 24916002
[TBL] [Abstract][Full Text] [Related]
33. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis C virus screening and treatment in Irish prisons from a governor and prison officer perspective - a qualitative exploration.
Crowley D; Van Hout MC; Murphy C; Kelly E; Lambert JS; Cullen W
Health Justice; 2018 Dec; 6(1):23. PubMed ID: 30569249
[TBL] [Abstract][Full Text] [Related]
35. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis.
Vescio MF; Longo B; Babudieri S; Starnini G; Carbonara S; Rezza G; Monarca R
J Epidemiol Community Health; 2008 Apr; 62(4):305-13. PubMed ID: 18339822
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis C antibody prevalence among Mexico City prisoners injecting legal and illegal substances.
Silverman-Retana O; Serván-Mori E; McCoy SI; Larney S; Bautista-Arredondo S
Drug Alcohol Depend; 2017 Dec; 181():140-145. PubMed ID: 29054033
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for prevalent hepatitis C virus-infection among inmates in a state prison system in Mexico.
Belaunzarán-Zamudio PF; Mosqueda-Gomez JL; Macias-Hernandez A; Sierra-Madero JG; Ahmed S; Beyrer C
PLoS One; 2017; 12(6):e0179931. PubMed ID: 28654650
[TBL] [Abstract][Full Text] [Related]
38. High-risk drug-use practices among a large sample of Australian prisoners.
Kinner SA; Jenkinson R; Gouillou M; Milloy MJ
Drug Alcohol Depend; 2012 Nov; 126(1-2):156-60. PubMed ID: 22658284
[TBL] [Abstract][Full Text] [Related]
39. Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study.
Cunningham EB; Hajarizadeh B; Bretana NA; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Dolan K; Lloyd AR; Grebely J;
J Viral Hepat; 2017 Sep; 24(9):733-741. PubMed ID: 28256027
[TBL] [Abstract][Full Text] [Related]
40. [Seroprevalence of hepatitis C virus infection at the time of entry to prison in the prison population in the north-east of Spain].
Martín Sánchez V; Ferrer Castro V; Pallas Álvarez JR; Alonso Herrero LE; Andrés Honorato M; Coterillo González MJ; García Marcos LS; González Márquez J; Hernández Alonso I; LLanos Gallegos M; Mallada García E; Martínez Martínez ML; Morillo Pérez M; Pérez Martínez I; Valles Martínez J
Rev Esp Salud Publica; 1998; 72(1):43-51. PubMed ID: 9477715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
